Mutual of America Capital Management LLC Has $5.45 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Mutual of America Capital Management LLC cut its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report) by 2.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,458 shares of the company’s stock after selling 321 shares during the period. Mutual of America Capital Management LLC’s holdings in IDEXX Laboratories were worth $5,448,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of IDXX. Moneta Group Investment Advisors LLC raised its stake in IDEXX Laboratories by 121,647.2% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 7,447,279 shares of the company’s stock valued at $3,038,192,000 after buying an additional 7,441,162 shares during the period. State Street Corp lifted its holdings in IDEXX Laboratories by 2.6% during the 2nd quarter. State Street Corp now owns 3,771,574 shares of the company’s stock valued at $1,894,198,000 after purchasing an additional 97,303 shares during the last quarter. Alliancebernstein L.P. boosted its position in IDEXX Laboratories by 6.4% during the second quarter. Alliancebernstein L.P. now owns 3,592,832 shares of the company’s stock worth $1,804,428,000 after purchasing an additional 214,529 shares during the period. Geode Capital Management LLC increased its holdings in shares of IDEXX Laboratories by 3.4% in the second quarter. Geode Capital Management LLC now owns 2,012,999 shares of the company’s stock valued at $1,008,862,000 after purchasing an additional 66,660 shares during the last quarter. Finally, Franklin Resources Inc. raised its position in shares of IDEXX Laboratories by 6.9% in the second quarter. Franklin Resources Inc. now owns 1,447,015 shares of the company’s stock valued at $726,734,000 after purchasing an additional 93,073 shares during the period. 86.85% of the stock is owned by institutional investors.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 7,128 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $513.05, for a total value of $3,657,020.40. Following the sale, the chief executive officer now owns 79,233 shares of the company’s stock, valued at approximately $40,650,490.65. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, EVP James F. Polewaczyk sold 11,636 shares of the stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $521.79, for a total value of $6,071,548.44. Following the completion of the transaction, the executive vice president now owns 10,050 shares of the company’s stock, valued at approximately $5,243,989.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 7,128 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $513.05, for a total transaction of $3,657,020.40. Following the completion of the sale, the chief executive officer now owns 79,233 shares in the company, valued at approximately $40,650,490.65. The disclosure for this sale can be found here. Insiders sold a total of 62,288 shares of company stock worth $34,600,528 over the last three months. Corporate insiders own 2.11% of the company’s stock.

Analysts Set New Price Targets

IDXX has been the subject of several research analyst reports. Barclays lifted their target price on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. The Goldman Sachs Group increased their target price on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. BNP Paribas began coverage on IDEXX Laboratories in a research note on Thursday, December 7th. They issued an “outperform” rating and a $602.00 price target for the company. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a report on Friday, January 5th. Finally, Piper Sandler downgraded IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price for the company. in a report on Tuesday, January 30th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average target price of $591.50.

Read Our Latest Analysis on IDXX

IDEXX Laboratories Stock Performance

IDXX opened at $572.21 on Monday. The firm has a market cap of $47.55 billion, a P/E ratio of 56.82, a price-to-earnings-growth ratio of 3.14 and a beta of 1.25. The business’s fifty day moving average is $540.92 and its 200-day moving average is $490.92. IDEXX Laboratories, Inc. has a 52-week low of $372.50 and a 52-week high of $579.68. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.17 and a current ratio of 1.57.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last announced its quarterly earnings data on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.12 by $0.20. The firm had revenue of $901.60 million for the quarter, compared to the consensus estimate of $891.88 million. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period in the prior year, the company posted $2.05 earnings per share. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.13 EPS for the current fiscal year.

About IDEXX Laboratories

(Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Read More

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.